Asian Journal of Pharmaceutical Technology & Innovation

ISSN: 2347-8810

Received on: 30-06-2014 Accepted on: 11-07-2014 Published on: 15-08-2014

Corresponding Author:

* Pramod Singh Khatri

Head of Department & Programme Coordinator, Clinical Research, Amity Medical School, Amity University, Haryana, India.

QR Code AJPTI



*Email Idpramodsinghkhatri@gmail.com Review Article

The Dawning Era of Nano Medicine for Anti-Cancer Therapy

Pramod Singh Khatri¹, Ritu Khatri²

ABSTRACT

Nanotechnology gives a mixed bag of Nano scale instruments for medicine. Cancer Nano therapeutics is quickly advancing and is continuously being actualized to tackle a few confinements of drug delivery systems for example nonspecific biodistribution and focusing on, absence of water dissolvability, poor oral bioavailability, and low therapeutic indices. To enhance the bio distribution of cancer medications, nanoparticles have been intended for ideal size and surface characteristics to build their circulation time in the circulatory system. They are likewise fit to convey their stacked active drugs to cancer cells by specifically utilizing the extraordinary pathophysiology of tumors, for example, their upgraded permeability and retention impact and the tumor microenvironment. Notwithstanding this aloof focusing on mechanism, active focusing on methods utilizing ligands or antibodies administered against chose tumor targets enhance the specificity of these therapeutics nanoparticles.

Medicine resistance, an alternate obstruction that blocks the viability of both molecularly focused on and routine chemotherapeutic executors, may additionally be succeed, or in any event diminished, utilizing nanoparticles. Nanoparticles have the capacity to accumulate in cells without being perceived by P-glycoprotein, one of the principle arbiters of multidrug resistance, bringing about the expanded intracellular concentration of medications. Multifunctional & multiplex nanoparticles are presently being energetically explored and are coming soon as the next era of nanoparticles, encouraging customized and custom-made tumor treatment.

Key-words: Anti cancer treatment, Nano particles, Nano medicine, Nanotechnology, P- glycoprotein, Nano carbon tubes

Cite this article as:

Pramod Singh Khatri, Ritu Khatri, Angiogenesis: The Dawning Era of Nano Medicine for Anti-Cancer Therapy, Asian Journal of Pharmaceutical Technology & Innovation, 02 (07); 2014.

1 HOD, Clinical Research, Amity Medical School, Amity University, Haryana, India.

2 MSc. Physics Student, Jodhpur National University, Rajasthan, India.

Pramod Singh Khatri et al., Asian Journal of Pharmaceutical Technology & Innovation, 02 (07); 2014; 78–86 Introduction

Nanotechnology is having a huge effect on drug delivery. There is a developing enthusiasm toward incorporating nanotechnology with pharmaceutical drugs, making purported Nano medicine going for illness diagnosis and treatment with extraordinary accuracy and viability (Folkman et al, 1964).

In the last few years, assets apportioned to the development of Nano medicine expanded significantly, highlighting the vitality of this advancing field. In drug delivery, Nano medicine is the latest created term to depict nanometer sized (1 – 1000 nm) (Fig: 1), multi-component medication for illness treatment (Alexiou et al, 2006).

The current challenge of drug delivery is to outline vehicles that can convey sufficient medications, effectively cross different physiological obstructions to reach disease destinations, and cure illnesses in a less dangerous and managed way (Yib et al ,2006). As most physiological obstructions disallow the penetration or disguise of particles or drug molecule with vast sizes and undesired surface properties, the fundamental input of nanotechnology on Nano medicine is to scale down and multifunctionalize drug transporters for enhanced drug delivery in a time frame and ailment specific manner (Gao X et al ,2002).



In spite of the fact that Nano medicine was conceptualized latestly, nanotechnology has been utilized in drug delivery for a considerable length of time. For instance, Nano particulate liposomes were initially introduced more than 40 years back. Today, a handful of liposome based, Nano particulate delivery vehicles have been endorsed by the FDA for clinical applications (Fig .2) (Lavan et al, 2002). The utilization of colloidal nanoparticles in drug delivery system is nearly 30 years old. They got to be clinically assuring when long circulating, stealth polymeric nanoparticles were created. Both micelles and polymer conjugates have been examined for more than two decades for the treatment of different maladies including cancer malignancy. The funding from both government and industry, the leaps forward in principal Nano scale science and engineering, and the advancement of translational science that coordinates medication and nanotechnology has affected and will keep on affecting the improvement of Nano medicine (Revets et al,2005).

System	characteristics	Example	Status
		•	
Polymeric Micelles	(a) Biocompatible ,biodegradable	PEG-PAA-DOX	Clinical Trials
	(b) Targeting Potential	Albumin -Taxol	Market
	(c) water soluble drug, nontoxic	Xyotax	Clinical Trials
Dendrimers	(a) Multi functionality , biodistribution	PAMAM -MTX	Preclinical
	(b) Chemical Homogeneity, tuned PK	PAMAM -Platinate	Preclinical
	(c) High ligand density		
Polymeric Nano	(-) (-)	A 1	Maalaat
particles	(a) Selective EPR effect , Pegylation	Abraxane	Market
	(b) water soluble ,biodegradable ,nontoxic	Camptothecin	Clinical Trials
Liposomes	(a) Biocompatible ,Amphiphilic	Doxil	Market
	(b) targeting potential ,Ease of Modification	Myocet	Market
Viral Nano particles	(a) Multi functionality	CPMV -DOX	Preclinical
	(b) water soluble ,biocompatible	HSP-DOX	Preclinical
			Clinical
Carbon Nanotubes	(a) Water Soluble, Biocompatible	CNT-MTX	Trials
	(b) Multi functionality	B	Clinical Trials

Fig.2 Types of Nano-Particles for drug delivery

Cancer as Drug Delivery Target

Tumor veins have a few anomalies contrasted with physiological vessels, for example, a generally high extent of multiplying endothelial cells, an amplified tortuosity and an atypical cellar membrane development (Chan WC et al ,2002). The quickly growing tumor vasculature frequently has a broken endothelium, with crevices between the cells that may be a few hundred nanometers in size (Brannor Peppas et al ,2004). Macro molecular transport pathways cross over tumor vessels happen by means of open holes (inter-endothelial intersections and Trans endothelial channels), vesicular vacuolar organelles and fenestrations. Notwithstanding, it stays dubious which pathways are transcendently in charge of tumor hyper permeability and macromolecular Trans vascular transport (Roy et al, 2003).

Tumor interstitium is additionally portrayed by a high interstitial pressure, prompting an outward convective interstitial fluid flow, and also the nonattendance of an anatomically decently defined working lymphatic system (Zou Y et al, 2004). Henceforth, the transport of an anticancer medication in the interstitium will be legislated by the physiological (i.e., pressure) and physico-chemical (i.e., organization, structure) properties of the interstitium and by the physico-chemical properties of the atom itself (i.e., size, configuration, charge, hydrophobicity) (Yauthey et al, 2002). Physiological boundaries at the tumor level (i.e., crudely vascularized tumor locales, high interstitial pressure and low micro vascular pressure) and in addition at the cell level (i.e., modified action of specific enzyme, changed apoptosis regulation and transport based mechanisms) and in the body (i.e., dispersion, biotransformation and freedom of anti-cancer agent) must be overcome to deliver anticancer agents to tumor cell in vivo (Bellorro et al, 2004).

Pramod Singh Khatri et al., Asian Journal of Pharmaceutical Technology & Innovation, 02 (07); 2014; 78–86

Colloidal nanoparticles fusing anticancer executors can overcome such resistances to medication activity, expanding the selectivity of medications towards cancer cells and lessening their harmfulness towards typical cells (Gao X et al, 2002).

The collection mechanism of intravenously infused nanoparticles in cancer malignancy tissues depends on a passive diffusion or convection over the hyper permeable tumor vasculature. Extra maintenance of the colloidal particles in the tumor interstitium is because of the bargained leeway through lymphatics (Duncan et al, 1984). This supposed "upgraded permeability and retention effect" brings about a vital intra tumoral medication gathering that is significantly higher than that is observed in plasma and in different tissues. Controlled arrival of the medication content inside the tumoral interstitium may be attained by controlling the Nano particulate structure, the polymer utilized and the path by which the medication is connected with the transporter (adsorption or encapsulation) (Cegnar et al ,2005).

In any case, anticancer medications, regardless of the possibility that they are placed in the tumoral interstitium, can have constrained efficacy against various tumor types in light of the fact that malignancy cells can create mechanism of resistance (Jordon et al, 2006). Synchronous cell imperviousness to numerous lipophilic medications is a standout amongst the most critical issues in chemotherapy. This medication resistance may show up clinically either as an absence of tumor size decrease or as the event of clinical backslide after a starting positive reaction to antitumor treatment. Multidrug resistance is chiefly because of overexpression of the plasma membrane P-glycoprotein, which is equipped for expelling positively charged xenobiotics, including some anticancer medications, out of the cell(Yang YY et al,2006). Multi drug resistance is constantly multifactorial when different mechanism could be connected with this medication efflux pump in cancer malignancy cells, for example, enzymatic function modification (e.g. topoisomerase, glutathione S-transferase) or changed intracellular medication dispersion because of expanded medication sequestration into cytoplasmic acidic vesicles. P-glycoprotein most likely perceives the medication to be effluxed out of the cancer cell just when the medication is available in the plasma membrane, and not when it is placed in the cytoplasm of lysosomes, after endocytosis. Numerous cancer cell types can create imperviousness to doxorubicin, which is a P-glycoprotein substrate, hence joining of this compound into nanoparticles to invert multidrug resistance (Ariciola et al, 2003).

P-glycoprotein interceded has been broadly examined. Certain sorts of nanoparticles can overcome multidrug resistance interceded by the P- glycoprotein, for example, poly (alkyl cyanoacrylate) nanoparticles. The delivery of anticancer executors to an exceedingly perfused tumoral injury and the tumor cells reaction have been portrayed through the development of a two dimensional tumor test system with the proficiency of demonstrating tumoral sore progression through the phases of diffusion-constrained torpidity, neo-vascularization and ensuing quick development and tissue attack(Westphal et al ,2003). Two-dimensional reproductions focused around a self-reliable parameter estimation showed key convective and diffusive transport impediments in delivering anticancer medication into tumors by means of intravenous free medication administration or through 100 nm nanoparticles infused into the circulation system, fit to extravagate and discharge the medication into the tumoral tissue, or by means of 1–10 nm nanoparticles, fit to diffuse specifically and target on the individual tumor cell(Lou B et al ,2005). Indeed with steady medication discharge from the nanoparticles, homogenous medication touchy tumor cell types, focused on nanoparticle delivery and model parameters aligned to guarantee sufficient medication or nanoparticle blood concentration to execute all cells in vitro, examination demonstrates that central transport confinements are extreme and that medication levels inside the tumor are far not exactly in vitro

www.asianpharmtech.com

(Maeda et al ,2001). This leaves substantial parts of the tumor with insufficient medication concentration. Examination of cell death rates anticipated by reenactments uncovers that the in vivo rate of tumor diminishment is a few orders of size less than in vitro for equivalent chemotherapeutic carrier concentrations in the blood. Little nanoparticles outfitted with dynamic transport systems would defeat the anticipated confinements and bring about encouraged tumor response (Photos et al ,2003).

Nanoparticles as Anticancer Drug Delivery framework

The destiny of a medication after administration in vivo is dictated by a combination of a few techniques, for example, distribution, digestion and elimination when given intravenously or ADME when an extravascular route is utilized. The result depends essentially on the physicochemical properties of the medication and consequently on its synthetic structure. From last decades, much work has been steered towards creating delivery frameworks to control the destiny of medications by changing these techniques, specifically the medication appropriation inside the organism (Pluen et al, 2001). Nanoparticles stacked with anticancer agents can effectively increase medicine concentration in cancer tissues and furthermore act at cell levels, upgrading anti-tumor efficacy. They might be endocytosed or phagocytosed by cells, with resulting cell disguise of the epitomized medication. Nanoparticles may comprise of either a polymeric network (Nano spheres) or of a supply framework in which a slick or fluid center is encompassed by a dainty polymeric wall (Nano capsules). Suitable polymers for nanoparticles incorporate poly (alkyl cyanoacrylates), poly (methylidene malonate) and polyesters, for example, poly (lactic acid), poly (glycolic acid), poly (e-caprolactone) and their copolymers (Barratt et al, 2003).

Nanoparticles of biodegradable polymers can give controlled and focused delivery of the medication with better efficacy and less side effects. Lipophilic drugs, which have some solvency either in the polymer matrix or in the slick center of Nano capsules, are more promptly joined than hydrophilic compounds, despite the fact that the latter may be adsorbed onto the molecule surface. Nano spheres can additionally be shaped from regular macromolecules, for example, proteins and polysaccharides, from non-polar lipids, and from inorganic materials, for example, metal oxides and silica (Langer et al ,1976).

As cancer chemotherapeutic executors are regularly regulated systemically, various biotic components connected with the tumor, influence the delivery of the medications to the tumors. Subsequently, drug delivery frameworks to solid tumors have been redesigned and hence, injectable delivery frameworks (i.e., solid lipid nanoparticles) have been produced as an option to polymeric nanoparticles for satisfactory drug delivery to solid tumors (Michalet et al ,2005).

These particles can profound infiltrate tissues, experiencing the fenestration of the little vein epithelial tissue(Fig. 3). They can enter the systemic blood circulation without shaping blood platelet aggregates. Their lessened molecule size involves high surface area and subsequently a system for speedier medication discharge. Drug delivery rates and molecule reliability might be adjusted and controlled by designing bearers in such a route, to the point that they could be initiated by progressions in the natural pH, compound jolts by the application of a quickly wavering magnetic field, or by application of an outside high temperature source (Gros L et al ,1981).

Therapeutic and analytic agents could be typified, covalently appended, or adsorbed into such Nano carriers while the nanoparticle surface might be functionalized with manufactured polymers and fitting ligands. Such procedures empower analysts to balance the pharmacokinetic profiles of injectable Nano crystals which may fluctuate from quickly dissolvable in the blood to gradually dissolving, making the medication discharge framework controllable (Schmitt –sody et al, 2003).

Pramod Singh Khatri et al., Asian Journal of Pharmaceutical Technology & Innovation, 02 (07); 2014; 78–86 Fig. 3 Nanoparticle delivery starts from blood stream



Routes for Nanoparticles Administration

The most advantageous route of medication administration is the oral one yet this displays a few boundaries to the utilization of colloidal bearer owing to circumstances inside the gastro-intestinal tract. Duodenal catalysts and bile salts obliterate the lipid bilayers of most types of liposome, discharging the medication. Polymeric nanoparticles are steadier, in spite of the fact that there is some proof that polyesters might be debased by pancreatic lipases (Bustanji et al, 2003). They may have the capacity to enhance bioavailability, especially for very insoluble medications, by expanding the surface zone for dissolution and as a consequence of bio adhesion. On the other hand, nanoparticles might be utilized to protect a labile medication from debasement in the gastrointestinal tract or to secure it from poisonous quality because of the medication (Lee Lj et al, 2006).

Polymeric nanoparticles, because of their bio adhesive properties, may be immobilized inside the bodily fluid or, when in contact with the epithelial cells, demonstrate a slower freedom from the gastrointestinal tract (Shvedova et al, 2003). Nanoparticles of biodegradable polymers (vitamin E TPGS) have been proposed to supplant the current system for clinical administration and to give an imaginative answer for oral chemotherapy. Vitamin E TPGS could be an innovative surfactant as well as a framework material when mixed with other biodegradable polymers – it has extraordinary advantage for the manufacture of polymeric nanoparticles for controlled release of paclitaxel and other anticancer medications (Weissleder et al, 2005).

Potential applications of colloidal medication bearers by the intravenous route could be outlined as amassing medications in available sites, rerouting medications far from destinations of danger and expanding the circulation time of labile or quickly wiped out medications (Paciotti et al ,2004).

Gene Therapy

Delivery frameworks are fundamental for molecules, for example, antisense oligonucleotides since they are defenseless to nuclease-interceded degradation in the blood circulation and enter crudely through the membrane. They are additionally vulnerable to nuclease assault inside the lysosomes and their site of action is either in the cytoplasm on account of an antisense procedure or in the nucleus for gene substitution or anti-gene therapy(Fig .4) (Ozkan et al ,2004).

Antisense oligonucleotides are particles that can hinder gene expression being possibly dynamic for the treatment of cancer malignancy. Short nucleic acid sequence specific to oncogene targets, for example, bcl-2, bcr-abl and c-myc have been demonstrated to display specific anticancer action in vitro through antigene or antisense activity (Hunter et al ,2002). In such case, their negative charge genuinely prevents the intracellular infiltration of these short fragments of nucleic acid. Efficient in

vivo delivery of oligonucleotides remains a real constraint for their remedial application (Farrer et al, 2005).



Toxicity Related Issues of nanoparticles

Dispersion of macromolecules, and in addition that of nanoparticles is a basic issue in drug delivery. The dissemination of microscopic objects through tissues is a multifactorial methodology, contingent upon tissue type, anatomical area, extracellular lattice composition and numerous different parameters. Delivery, association and relative levels of collagen, decorin and hyaluronan, case in point, are known to debilitate the dissemination of macromolecules and nanoparticles in tumors (Panyan et al, 2002).

In spite of the fact that nanoparticles are perfect instruments to tweak and conquer the dissolvability and solidness issues of medication administration, questions have been raised with respect to their lethality (Kukowska Latallo et al, 2005). Indeed, over the recent years, various toxicology reports have showed that exposure to certain nanotechnology inferred particles posture genuine dangers to biological frameworks. For example, exposure of human keratinocytes to insoluble single-wall carbon nanotubes has been connected with oxidative anxiety and apoptosis (Clark et al, 1999).

Regular toxicity issues have frequently been disregarded in this energizing field of research. Cases in point are,

- what is a definitive destiny of Nano carriers and their constituents in the body, especially those which are not bio-degradable, such as functionalized carbon nanotubes and coating agents, for example, poly(ethylene glycol)?
- Can polymeric vectors utilized for gene delivery, and additionally other polymer-based biomaterials, meddle with cell apparatuses or prompt altered gene articulation?
- What are the long haul results?
- What exactly degree would we be able to interpret cell and immunological toxicity results observed in animals models to human?

The issue of lethality gets to be especially genuine for intravenously infused nanoparticles, as the systemic circulation greatly enhances the likelihood of uncalled targets(Drummond et al ,2000). Loco-regional delivery could be a reasonable method for administration of nanoparticles, when intravenous organization is viewed as unsafe(Choi et al ,2005). However shouldn't we think about neighborhood amassing of non-biodegradable objects?

Closing Remarks

Because of the colossal capability of nanotechnology, science is altogether putting resources into this field. Together with the movement of Nano scale drug delivery frameworks, propels in Nano scale

Pramod Singh Khatri et al., Asian Journal of Pharmaceutical Technology & Innovation, 02 (07); 2014; 78–86

imaging propose the potential for the development of multifunctional ""brilliant"" nanoparticles that might encourage the acknowledgment of individualized cancer treatment. Very nearly numerous types of nanoparticles including polymeric nanoparticles, Nano crystals, polymeric micelles, Dendrimers, and carbon nanotubes have been assessed for their suitability as multifunctional nanoparticles that can be connected for synchronous in vivo imaging and treatment of tumors. In the long run, multiplex nanoparticles may be fit of catching threatening cells (dynamic focusing on moiety), imagining their area in the body (ongoing in vivo imaging), killing the tumor cells with negligible symptoms by saving typical cells (dynamic focusing on and controlled medication discharge or photo thermal removal), and checking treatment impacts progressively.

Meanwhile, researchers ought not to neglect to legitimately deliver issues identified with the connection of nanomaterial with biotic frameworks and conceivable wellbeing issues, if effective and productive application of these advances is going to be attained. The eventual fate of Nano medicine will rely upon reasonable outline of nanotechnology materials and instruments based around a point by point and exhaustive understanding of the living procedures as opposed to the compelling applications of a few materials as of now in vogue.

Acknowledgement:

I wish to thank the student for her critical discussion.

Conflicts of Interest Statement:

The Authors declare no conflicts of interest.

References

- 1. Arciola CR, Bustanji Y, Conti M *et al*: Staphylococcus epidermidis-fibronectin binding and its inhibition by heparin. Biomaterials *24(18)*: 3013-3019, 2003.
- 2. Bustanji Y, Arciola CR, Conti M, Mandello E, Montanaro L and Samori B: Dynamics of the interaction between a fibronectin molecule and a living bacterium under mechanical force. Proc Natl Acad Sci USA *100(23)*: 13292-13297, 2003.
- 3. Barratt G: Colloidal drug carriers: achievements and perspectives.Cell Mol Life Sci 60(1): 21-37, 2003.
- 4. Schmitt-Sody M, Strieth S, Krasnici S *et al*: Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res *9(6)*: 2335-2341, 2003.
- 5. Shukla GS and Krag DN: Selective delivery of therapeutic agents for the diagnosis and treatment of cancer. Expert Opin Biol Ther*6*(*1*): 39-54, 2006.
- 6. Cegnar M, Kristl J and Kos J: Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours. Expert Opin Biol Ther *5(12)*: 1557-1569, 2005.
- 7. Yih TC and Al-Fandi M: Engineered nanoparticles as precise drug delivery systems. J Cell Biochem *97(6)*: 1184-1190, 2006.
- 8. Chan WC, Maxwell DJ, Gao X, Bailey RE, Han M and Nie S: Luminescent quantum dots for multiplexed biological detection and imaging. Curr Opin Biotechnol *13(1)*: 40-46, 2002.
- 9. Gao X, Chan WC and Nie S: Quantum-dot nanocrystals for ultrasensitive biological labeling and multicolor optical encoding. J Biomed Opt *7(4)*: 532-537, 2002.
- 10. Gao X, Cui Y, Levenson RM, Chung LW and Nie S: *In vivo* cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22(8): 969-976, 2004.
- 11. Michalet X, Pinaud FF, Bentolila LA *et al*: Quantum dots for live cells, *in vivo* imaging, and diagnostics. Science *307(5709)*: 538-544,2005.
- 12. Drummond DC, Zignani M and Leroux J: Current status of pH- sensitive liposomes in drug delivery. Prog Lipid Res *39(5)*: 409-460, 2000.
- 13. Panyam J, Zhou WZ, Prabha S, Sahoo SK and Labhasetwar V: Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. Faseb J *16(10)*: 1217-1226, 2002.
- 14. Clark HA, Hoyer M, Philbert MA and Kopelman R: Optical nanosensors for chemical analysis inside single living cells. 1. Fabrication, characterization, and methods for intracellular delivery of PEBBLE sensors. Anal Chem 71(21): 4831-4836, 1999.
- 15. Farrer RA, Butterfield FL, Chen VW and Fourkas JT: Highly efficient multiphoton-absorption-induced luminescence from gold nanoparticles. Nano Lett *5(6)*: 1139-1142, 2005.
- 16. Paciotti GF, Myer L, Weinreich D *et al*: Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv *11(3)*: 169-183, 2004.

- 17. Ozkan M: Quantum dots and other nanoparticles: what can they offer to drug discovery? Drug Discov Today *9(24)*: 1065-1071, 2004.
- 18. Choi Y and Baker JR Jr: Targeting cancer cells with DNA- assembled dendrimers: a mix and match strategy for cancer. Cell Cycle *4*(*5*): 669-671, 2005.
- 19. Kukowska-Latallo JF, Candido KA, Cao Z *et al*: Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res *65(12)*: 5317-5324, 2005.
- 20. Yang YY, Wang Y, Powell R and Chan P: Polymeric core-shell nanoparticles for therapeutics. Clin Exp Pharmacol Physiol 33(5-6): 557-562, 2006.
- 21. Revets H, De Baetselier P, Muyldermans S: Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther 5(1): 111-124, 2005.
- 22. Lou B, Liao XL, Wu MP, Cheng PF, Yin CY and Fei Z: High- density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J Gastroenterol *11(7)*: 954-959, 2005.
- 23. Bellomo, E. G.; Wyrsta, M. D.; Pakstis, L.; Pochan, D. J.; Deming, T. J. "Stimuli-responsive polypeptide vesicles by conformation-specific assembly", Nat. Mater. 2004, 3, 244–248.
- 24. Photos, P. J.; Bacakova, L.; Discher, B.; Bates, F. S.; Discher, D. E. "Polymer vesicles in vivo: Correlations with PEG molecular weight", J. Controlled Release 2003, 90, 323–334.
- 25. Vauthey, S.; Santoso, S.; Gong, H. Y.; Watson, N.; Zhang, S. G. "Molecular self-assembly of surfactant-like peptides to form nanotubes and nanovesicles", Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 5355–5360.
- 26. Gros, L.; Ringsdorf, H.; Schupp, H. "Polymeric anti-tumor agents on a molecular and on a cellular-level", Angew. Chem. Int. Ed. Engl. 1981, 20, 305–325.
- 27. Duncan, R.; Kopecek, J. "Soluble synthetic polymers as potential drug carriers", Adv. Polym. Sci. 1984, 57, 51–101.
- 28. Maeda, H. "SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy", Adv. Drug Deliv. Rev. 2001, 46, 169–185.
- 29. Folkman, J.; Long, D. M. "The use of silicone rubber as a carrier for prolonged drug therapy", J. Surg. Res. 1964, 4, 139–142.
- 30. Langer, R.; Folkman, J. "Polymers for sustained-release of proteins and other macromole- cules", Nature 1976, 263, 797-800.
- 31. Westphal, M.; Hilt, D. C.; Bortey, E.; Delavault, P.; Olivares, R.; Warnke, P. C.; Whittle, I. R.; Jaaskelainen, J.; Ram, Z. "A phase 3 trial of local chemotherapy with biodegradable carmus- tine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma", Neuro- Oncology 2003, 5, 79–88.
- 32. Weissleder R, Kelly K, Sun EY, Shtatland T and Josephson L: Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol *23(11)*: 1418-1423, 2005.
- 33. Jordan A, Scholz R, Maier-Hauff K *et al*: The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol *78(1)*: 7-14, 2006.
- 34. Alexiou C, Schmid RJ, Jurgons R *et al*: Targeting cancer cells: magnetic nanoparticles as drug carriers. Eur Biophys J *35*(*5*): 446- 450, 2006.
- 35. Zou Y, Fu H, Ghosh S, Farquhar D and Klostergaard J: Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin Cancer Res *10(21)*: 7382-7391, 2004.
- 36. Brannon-Peppas L and Blanchette JO: Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev *56(11)*: 1649-1659,2004.
- 37. Roy I, Ohulchanskyy TY, Pudavar HE *et al*: Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc *125(26)*: 7860-7865, 2003.
- 38. Lee LJ: Polymer nano-engineering for biomedical applications. Ann Biomed Eng *34(1)*: 75-88, 2006.
- 39. Lu Z, Yeh TK, Tsai M, Au JL and Wientjes MG: Paclitaxel- loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res *10(22)*: 7677-7684, 2004.
- 40. Pluen A, Boucher Y, Ramanujan S *et al*: Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci USA *98(8)*: 4628-4633,2001.
- 41. Hunter AC and Moghimi SM: Therapeutic synthetic polymers: a game of Russian roulette? Drug Discov Today *7(19)*: 998-1001, 2002.
- 42. Shvedova AA, Castranova V, Kisin ER *et al*: Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells. J Toxicol Environ Health A *66(20)*:1909-1926, 2003.
- 43. LaVan DA, Lynn DM and Langer R: Moving smaller in drug discovery and delivery. Nat Rev Drug Discov 1(1): 77-84, 2002.